Synergistic antimicrobial therapy using nanoparticles and antibiotics for the treatment of multidrug-resistant bacterial infection
Synergistic antimicrobial therapy using nanoparticles and antibiotics for the treatment of multidrug-resistant bacterial infection
复制标题
DOI：
10.1088/2399-1984/aa69fb
复制
发表时间：
2017-06-01
期刊：
影响因子：
2.1
通讯作者：
Rotello, Vincent M.
中科院分区：
文献类型：
--
作者：
Gupta, Akash;Saleh, Neveen M.;Rotello, Vincent M.
多重耐药（MDR）细菌引起的感染造成严重的全球死亡负担，每年导致数千人死亡。耐药感染的抗生素治疗进一步导致抗生素耐药物种和菌株数量的迅速增加。纳米颗粒 (NP) 等合成大分子对 MDR 物种表现出广谱活性，但相对于哺乳动物宿主而言，对细菌缺乏特异性，限制了其广泛的治疗应用。在这里，我们展示了使用疏水功能化纳米颗粒和氟喹诺酮抗生素的协同抗菌疗法来治疗 MDR 细菌菌株。在使用工程化纳米粒子来对抗 MDR 菌株的情况下，抗生素剂量可减少 8-16 倍。这一策略证明了使用纳米颗粒“复活”因病原菌产生耐药性而失效的抗生素的潜力。
Infections caused by multidrug-resistant (MDR) bacteria pose a serious global burden of mortality, causing thousands of deaths each year. Antibiotic treatment of resistant infections further contributes to the rapidly increasing number of antibiotic-resistant species and strains. Synthetic macromolecules such as nanoparticles (NPs) exhibit broad-spectrum activity against MDR species, however lack of specificity towards bacteria relative to their mammalian hosts limits their widespread therapeutic application. Here, we demonstrate synergistic antimicrobial therapy using hydrophobically functionalized NPs and fluoroquinolone antibiotics for treatment of MDR bacterial strains. An 8-16-fold decrease in antibiotic dosage is achieved in presence of engineered NPs to combat MDR strains. This strategy demonstrates the potential of using NPs to 'revive' antibiotics that have been rendered ineffective due to the development of resistance by pathogenic bacteria.